142 related articles for article (PubMed ID: 9248972)
1. The use of cefotaxime for the treatment of common infections: in vitro, pharmacokinetic and clinical considerations.
Wilson WR; Bouza E; Lode H; Mouton Y
J Chemother; 1997 May; 9 Suppl 2():5-18. PubMed ID: 9248972
[TBL] [Abstract][Full Text] [Related]
2. Clinical features and therapeutic implications of 104 episodes of monomicrobial Aeromonas bacteraemia.
Ko WC; Lee HC; Chuang YC; Liu CC; Wu JJ
J Infect; 2000 May; 40(3):267-73. PubMed ID: 10908022
[TBL] [Abstract][Full Text] [Related]
3. Limiting cefotaxime pediatric dosing to adult standards: a pharmacokinetic simulation study.
Dulaney Lopez AM; Rodriguez JC; Lopez-Samblas AM; Estes KS
Int J Clin Pharmacol Ther; 1999 Jun; 37(6):269-74. PubMed ID: 10395117
[TBL] [Abstract][Full Text] [Related]
4. [Cefotaxime in sequential therapy of community acquired pneumonia].
Wolska-Goszka L; Petlak A; Słomiński JM
Pol Merkur Lekarski; 1999 Sep; 7(39):99-101. PubMed ID: 10598482
[TBL] [Abstract][Full Text] [Related]
5. The choice of antibacterial drugs.
Med Lett Drugs Ther; 1998 Mar; 40(1023):33-42. PubMed ID: 9549552
[No Abstract] [Full Text] [Related]
6. Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.
Brogden RN; Spencer CM
Drugs; 1997 Mar; 53(3):483-510. PubMed ID: 9074846
[TBL] [Abstract][Full Text] [Related]
7. [The use of cefotaxime against infections (author's transl)].
Lepeu G; Bertrand A; Armengaud M; Aubertin J
Nouv Presse Med; 1981 Feb; 10(8):594-7. PubMed ID: 6259600
[TBL] [Abstract][Full Text] [Related]
8. [Clinical trial of a new broad-spectrum cephalosporin: HR 756 (cefotaxime)].
Poletti T; Bertola D; Pellerito R; Soragna A
Minerva Med; 1980 Jul; 71(27):1935-43. PubMed ID: 6248823
[TBL] [Abstract][Full Text] [Related]
9. [Clinical use of new cephalosporins for severe infections in internal medicine].
Stille W
Wien Klin Wochenschr Suppl; 1983; 142():18-20. PubMed ID: 6316668
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic options for cefotaxime in the management of bacterial infections.
Raddatz JK; Ostergaard BE; Rotschafer JC
Diagn Microbiol Infect Dis; 1995; 22(1-2):77-83. PubMed ID: 7587054
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of cefotaxime in healthy volunteers and patients.
Patel KB; Nicolau DP; Nightingale CH; Quintiliani R
Diagn Microbiol Infect Dis; 1995; 22(1-2):49-55. PubMed ID: 7587050
[TBL] [Abstract][Full Text] [Related]
12. [Cefotaxime in bronchopulmonary infections (author's transl)].
Kermarec J; Sauvaget J
Nouv Presse Med; 1981 Feb; 10(8):650-3. PubMed ID: 6259612
[TBL] [Abstract][Full Text] [Related]
13. [Cost-effectiveness analysis of ceftriaxone and cefotaxime in the treatment of community-acquired pneumonia].
García-Contreras F; Del-Angel-García G; Ramírez Cuenca A; Malváez-Valdes M; Vega Yáñez A; Amato D
Rev Invest Clin; 2000; 52(4):418-26. PubMed ID: 11061104
[TBL] [Abstract][Full Text] [Related]
14. [Cefotaxime in the treatment of severe infections due to multiresistant Gram-negative bacilli (author's transl)].
Clumeck N; Van Laethem Y; Vanhoof R; Jaspar N; George G; Rapin M; Butzler JP
Nouv Presse Med; 1981 Feb; 10(8):622-4. PubMed ID: 6259606
[TBL] [Abstract][Full Text] [Related]
15. Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome.
Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Oh MD; Kim EC; Choe KW
Clin Infect Dis; 2004 Sep; 39(6):812-8. PubMed ID: 15472813
[TBL] [Abstract][Full Text] [Related]
16. Cefotaxime in the treatment of prophylaxis of surgical infections.
Wittmann DH; Jones RN; Malledant J; Privitera G
J Chemother; 1997 May; 9 Suppl 2():19-33. PubMed ID: 9248973
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic (kinetic) considerations in the treatment of moderately severe infections with cefotaxime.
Turnidge JD
Diagn Microbiol Infect Dis; 1995; 22(1-2):57-69. PubMed ID: 7587052
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
19. Pharmacoeconomic aspects of antibacterial treatment with cefotaxime.
Cooke J; Doreau C; Eandi M
J Chemother; 1997 May; 9 Suppl 2():34-45. PubMed ID: 9248974
[TBL] [Abstract][Full Text] [Related]
20. [Clinical evaluation of cefotaxime at various dosage levels in urinary tract infections (author's transl)].
Guibert J; Acar JF; Justin C; Kitzis MD
Nouv Presse Med; 1981 Feb; 10(8):625-7. PubMed ID: 6259607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
